Breaking

Russian International Reserves Fall $15.7 Billion in Week to Dec. 19
Tweet TWEET

Aratana Therapeutics Appoints Louise Mawhinney Chief Financial Officer

    Aratana Therapeutics Appoints Louise Mawhinney Chief Financial Officer

Mawhinney Brings Emerging Growth, IPO and Public Company Experience to Aratana
in Newly Created CFO Position

PR Newswire

KANSAS CITY, Kan. and NEW YORK, Sept. 27, 2012

KANSAS CITY, Kan. and NEW YORK, Sept. 27, 2012 /PRNewswire/ --Aratana
Therapeutics, an animal health company developing innovative medicines for
cats and dogs (companion animals), today announced it has appointed Louise
Mawhinney, CPA, as Chief Financial Officer. Aratana created the role of CFO
within the Company as part of a recent expansion of the senior management team
envisioned to accelerate growth and facilitate execution on upcoming
milestones.

Ms. Mawhinney brings more than 15 years of CFO experience to Aratana,
including both private and NASDAQ-listed life sciences companies. Most
notably, Ms. Mawhinney led the IPO team that took Helicos BioSciences Corp.
public in May 2007 and was the CFO of ArQule, Inc.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana
Therapeutics, stated, "Louise is a very experienced and dynamic executive who
is well known within the biotech community. I had the pleasure of working
with Louise when she helped complete Helicos' initial public offering during
my tenure as a member of the board. I am very pleased to work with her again
as we accelerate our growth and execute on several upcoming milestones."

Louise Mawhinney, CPA, Chief Financial Officer of Aratana Therapeutics,
stated, "I believe Aratana is pioneering a large and growing private-pay
market in companion animal medicine, where the need for innovative new
therapies is significant. I look forward to supporting the growth of the
Company at this important inflection point. "

Louise Mawhinney, CPA
Prior to joining Aratana Therapeutics, Ms. Mawhinney was Senior Vice President
and Chief Financial Officer of Ikonisys, Inc., a cell-based diagnostics
company. Previously, she was Chief Financial Officer at Helicos BioSciences
Corporation, a life sciences company, which Ms. Mawhinney was successful in
helping to take public in May 2007. Prior to Helicos, Ms. Mawhinney was
Chief Financial Officer for ArQule, Inc., a biotechnology company focused on
oncology. From 2000-2003, Ms. Mawhinney was Chief Financial Officer, and a
founding member, of eSpendwise, a provider of global eBusiness systems. Ms.
Mawhinney also served as Chief Financial Officer at The Butcher Company; Group
Controller at Lifetime Corporation; and a Senior Tax Specialist at KPMG in
Boston. Ms. Mawhinney holds a Masters Degree from the University of St.
Andrews in Scotland and has been a CPA in Massachusetts since 1989.

About Aratana Therapeutics
Aratana Therapeutics is an animal health drug development company uniquely
positioned to deliver high quality new medicines that address significant
therapeutic needs for cats and dogs (companion animals). Aratana licenses and
develops proprietary, patent-protected compounds acquired from human
pharmaceutical and biotechnology companies and then develops strategies to
maximize the value of the programs for the animal health market. For more
information, please visit www.aratanatherapeutics.com.

For Media & Investors:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jrando@tiberend.com
jdrumm@tiberend.com

SOURCE Aratana Therapeutics

Website: http://www.aratanatherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.